Results 51 to 60 of about 1,815 (184)

New Diabetes Therapies and Diabetic Kidney Disease Progression:the Role of SGLT-2 Inhibitors [PDF]

, 2018
Purpose of Review Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have emerged as a promising drug class for the treatment of diabetic kidney disease.
Dekkers, Claire C. J., Gansevoort, Ron T., Heerspink, Hiddo J. L.   +2 more
core   +2 more sources

Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Outcomes:True Renoprotection, Loss of Muscle Mass or Both? [PDF]

, 2020
Inhibitors of sodium-glucose cotransporter 2 (SGLT2) have emerged as practice-changing treatments for patients with type 2 diabetes, reducing both the risk of cardiovascular events and kidney events.
Bakker, Stephan J. L., Eisenga, Michele F., Groothof, Dion, Post, Adrian   +3 more
core   +1 more source

Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real‐world clinical practice: Results of 3‐month interim analysis of a long‐term post‐marketing surveillance study (J‐STEP/LT)

Journal of Diabetes Investigation, 2019
Aims/Introduction The present study analysis was carried out to evaluate the safety and efficacy of tofogliflozin, a sodium–glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus in real‐world clinical practice.
Kazunori Utsunomiya, Masayuki Senda, Seigo Kakiuchi, Hiroyuki Kameda, Masahiro Tamura, Yuji Kurihara, Ryoji Gunji, Shoko Fujii, Hisataka Fujiwara, Kohei Kaku   +9 more
doaj   +1 more source

Effectiveness of SGLT2 inhibitors compared to sulphonylureas for long-term glycemic control in type 2 diabetes: A meta-analysis. [PDF]

Biomol Biomed
Sulphonylureas (SUs) are common glucose-lowering agents used for managing type 2 diabetes mellitus (T2DM). However, their long-term effectiveness is often limited due to declining β-cell function.
Zhan Z, Wang J, Shen N, Liu X, Wang L.
europepmc   +3 more sources

Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study)

Contemporary Clinical Trials Communications, 2020
Background: The incidence of nonalcoholic fatty liver disease (NAFLD) has increased recently and is related to obesity and the associated surge in type 2 diabetes mellitus (DM) and metabolic syndrome diagnoses.
Anna Ozaki, Masato Yoneda, Takaomi Kessoku, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Eiji Sakai, Masataka Taguri, Takeharu Yamanaka, Tomoyuki Iwasaki, Takeo Kurihashi, Satoru Saito, Atsushi Nakajima   +14 more
doaj   +1 more source

Changes in the estimated glomerular filtration rate and predictors of the renal prognosis in Japanese patients with type 2 diabetes: A retrospective study during the 12 months after the initiation of tofogliflozin.

PLoS ONE, 2023
BackgroundThe changes in the estimated glomerular filtration rate (eGFR) and predictors of the renal prognosis were retrospectively assessed over the 12 months after the initiation of tofogliflozin, which has the shortest half-life among sodium-glucose ...
Hiroyuki Ito, Hideyuki Inoue, Takuma Izutsu, Suzuko Matsumoto, Shinichi Antoku, Tomoko Yamasaki, Toshiko Mori, Michiko Togane   +7 more
doaj   +1 more source

Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes

Journal of Clinical Medicine Research, 2016
Some patients with type 2 diabetes mellitus (T2DM) on insulin have poor glycemic control and require add-on therapy to reach target glucose values. Increased insulin doses or the addition of an oral antidiabetic drug (OAD) may improve glycemic control, but many patients fail to achieve target values.
Suzuki, Katsunori, Mitsuma, Yurie, Sato, Takaaki, Anraku, Takumi, Hatta, Mariko   +4 more
openaire   +3 more sources

Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Frontiers in Medicine, 2022
ObjectiveTo evaluate the effects of vitamin E, pioglitazone, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists in patients with non-alcoholic fatty liver disease (NAFLD).DesignA network meta-analysis.
Qian Luo, Qian Luo, Ruojun Wei, Ruojun Wei, Yuzi Cai, Yuzi Cai, Qihan Zhao, Qihan Zhao, Yuning Liu, Yuning Liu, Wei Jing Liu, Wei Jing Liu   +11 more
doaj   +1 more source

Tofogliflozin Salt Cocrystals with Sodium Acetate and Potassium Acetate

Chemical and Pharmaceutical Bulletin, 2018
We investigated the salt cocrystals formed by tofogliflozin with sodium acetate and potassium acetate by determining the crystal structures of the salt cocrystals and characterizing the solid states. The salt cocrystal screening using the slurry method and the liquid-assisted grinding method resulted in the formation of tofogliflozin-sodium acetate 1 : 
Noriyuki, Takata, Satoshi, Tanida, Shinichi, Nakae, Koji, Shiraki, Yuichi, Tozuka, Masaki, Ishigai   +5 more
openaire   +3 more sources

Effects of Tofogliflozin on Cardiac Function in Elderly Patients With Diabetes Mellitus

Journal of Clinical Medicine Research, 2020
Patients with type 2 diabetes mellitus (T2DM) are at increased risk for impairments in diastolic relaxation and heart failure with preserved ejection fraction (EF). Recent clinical data suggest that several sodium glucose transporter-2 (SGLT2) inhibitors are found to reduce cardiovascular disease (CVD) events in elderly diabetic patients, but the ...
Higashikawa, Toshihiro, Ito, Tomohiko, Mizuno, Takurou, Ishigami, Keiichirou, Kohori, Masaru, Mae, Kunihiro, Usuda, Daisuke, Takagi, Susumu, Sangen, Ryusho, Saito, Atsushi, Iguchi, Masaharu, Kasamaki, Yuji, Fukuda, Akihiro, Kanda, Tsugiyasu, Okuro, Masashi   +14 more
openaire   +3 more sources